Extending indication of cyclin-dependent kinase 4/6 inhibitors in the adjuvant and neoadjuvant setting

Purpose of review: A burst of recent activity has surrounded the study of cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors for the treatment of metastatic breast cancer. The success of these drugs in the metastatic setting has pushed the evaluation of these agents in early-stage disease. The use of CDK 4/6 inhibitors as neoadjuvant and adjuvant therapy is a hot topic and several studies are underway. Recent findings: Ongoing studies are exploring the addition of CDK 4/6 inhibitors to endocrine therapy in early breast cancer. Summary: Identification of the optimal treatment combinations is the goal of current research. Finding biomarkers for patients' selection will be the goal of future research.